Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy

References

• PeerDKarpJMHongSFarokhzadOCMargalitRLangerRNanocarriers as an emerging platform for cancer therapyNat Nanotechnol200721275176018654426
   PubMed Web of Science ®Google Scholar
• FerrariMCancer nanotechnology: opportunities and challengesNat Rev Cancer20055316117115738981
   PubMed Web of Science ®Google Scholar
• FarokhzadOCLangerRImpact of nanotechnology on drug deliveryACS Nano200931162019206243
   PubMed Web of Science ®Google Scholar
• CiuffredaLDi SanzaCIncaniUCMilellaMThe mTOR pathway: a new target in cancer therapyCurr Cancer Drug Targets201010548449520384580
   PubMed Web of Science ®Google Scholar
• SunSYRosenbergLMWangXActivation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibitionCancer Res200565167052705816103051
   PubMed Web of Science ®Google Scholar
• LiuQThoreenCWangJSabatiniDGrayNSmTOR mediated anti-cancer drug discoveryDrug Discov Today Ther Strateg200962475520622997
   PubMedGoogle Scholar
• KahanBDCamardoJSRapamycin: clinical results and future opportunitiesTransplantation20017271181119311602840
   PubMed Web of Science ®Google Scholar
• HoySMMcKeageKTemsirolimus: in relapsed and/or refractory mantle cell lymphomaDrugs201070141819182920836575
   PubMed Web of Science ®Google Scholar
• PanwalkarAVerstovsekSGilesFJMammalian target of rapamycin inhibition as therapy for hematologic malignanciesCancer2004100465766614770419
   PubMed Web of Science ®Google Scholar
• WangYEverolimus in renal cell carcinomaDrugs Today (Barc)201046855756620830316
   PubMed Web of Science ®Google Scholar
• AdjeiAAHidalgoMIntracellular signal transduction pathway proteins as targets for cancer therapyJ Clin Oncol200523235386540315983388
   PubMed Web of Science ®Google Scholar
• GuertinDASabatiniDMThe pharmacology of mTOR inhibitionSci Signal2009267pe2419383975
   PubMed Web of Science ®Google Scholar
• DiasVCYatscoffRWAn in vitro method for predicting in vivo oral bioavailability of novel immunosuppressive drugsClin Biochem199629143498929823
   PubMed Web of Science ®Google Scholar
• MaramattomBVWijdicksEFSirolimus may not cause neurotoxicity in kidney and liver transplant recipientsNeurology200463101958195915557524
   PubMed Web of Science ®Google Scholar
• LeeSWChangDHShimMSKimBOKimSOSeoMHIonically fixed polymeric nanoparticles as a novel drug carrierPharm Res20072481508151617380262
   PubMed Web of Science ®Google Scholar
• FrankenNARodermondHMStapJHavemanJvan BreeCClonogenic assay of cells in vitroNat Protoc2006152315231917406473
   PubMed Web of Science ®Google Scholar
• JeongSYParkSJYoonSMSystemic delivery and pre-clinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitizationJ Control Release2009139323924519619590
   PubMed Web of Science ®Google Scholar
• JeongSYYiSLLimSKEnhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthineInt J Pharm20093721–213213919167476
   PubMed Web of Science ®Google Scholar
• GrefRLuckMQuellecP‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorptionColloids Surf B Biointerfaces2000183–430131310915952
   PubMed Web of Science ®Google Scholar
• AvgoustakisKBeletsiAPanagiZEffect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticlesInt J Pharm20032591–211512712787641
   PubMed Web of Science ®Google Scholar
• KimSCKimDWShimYHIn vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacyJ Control Release2001721–319120211389998
   PubMed Web of Science ®Google Scholar
• AlbertJMKimKWCaoCLuBTargeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancerMol Cancer Ther2006551183118916731750
   PubMed Web of Science ®Google Scholar
• CaoCSubhawongTAlbertJMInhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cellsCancer Res20066620100401004717047067
   PubMed Web of Science ®Google Scholar
• ShinoharaETCaoCNiermannKEnhanced radiation damage of tumor vasculature by mTOR inhibitorsOncogene200524355414542215940265
   PubMed Web of Science ®Google Scholar
• AokiHKondoYAldapeKMonitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3Autophagy20084446747518259115
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• GubaMvon BreitenbuchPSteinbauerMRapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNat Med20028212813511821896
   PubMed Web of Science ®Google Scholar
• WanXHelmanLJThe biology behind mTOR inhibition in sarcomaOncologist20071281007101817766661
   PubMed Web of Science ®Google Scholar
• GuertinDASabatiniDMDefining the role of mTOR in cancerCancer Cell200712192217613433
   PubMed Web of Science ®Google Scholar
• SabatiniDMmTOR and cancer: insights into a complex relationshipNat Rev Cancer20066972973416915295
   PubMed Web of Science ®Google Scholar
• MorrisREIn vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and useTransplant Proc1991236272227241721257
   PubMed Web of Science ®Google Scholar
• SimamoraPAlvarezJMYalkowskySHSolubilization of rapamycinInt J Pharm20012131–2252911165091
   PubMed Web of Science ®Google Scholar
• Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779Drugs R D20045636336715563243
   PubMedGoogle Scholar
• RaymondEAlexandreJFaivreSSafety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancerJ Clin Oncol200422122336234715136596
   PubMed Web of Science ®Google Scholar
• MaedaHTumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospectsBioconjug Chem201021579780220397686
   PubMed Web of Science ®Google Scholar